Evaluation of CRP SNV rs2808630 and acute proinflammatory biomarkers in patients with CKD and PLHIV with CKD: a case-control study

Table 3 Concentrations of hs-CRP, IL-6 and kidney function biomarkers by genotypes

	Groups	TT ^{me (IQR)}	TC ^{me (IQR)}	CC ^{me (IQR)}	P
hs-CRP	CKD	4.001 (1.044–9.122)	2.876 (0.943–7.355)	1.752 (0.225–3.278)	0.2693^a
hs-CRP	PLHIV with CKD	2.033 (0.791–5.781)	2.826 (1.611–6.803)	0.730 (0.209–3.848)	0.2180^a
IL-6	CKD	6.409 (3.788–23.91)	6.091 (2.578–14.02)	7.871 (5.392–10.35)	0.5076^a
IL-6	PLHIV with CKD	2.772 (1.513–6.334)	3.570 (1.307–5.194)	3.821 (2.744–90.65)	0.5920^a
Creatinine	CKD	16.60 (4.850–35.65)	4.510 (1.620–10.69)	18.17 (9.34-27.00)	< 0.0001^a*
Creatinine	PLHIV with CKD	1.480 (1.300-2.015)	1.420 (1.210–1.660)	2.420 (1.4203.490)	0.3262^a
eGFR	CKD	4.010 (1.825–10.36)	13.50 (4.710–38.90)	4.055 (2.450–5.660)	< 0.0001^a*
eGFR	PLHIV with CKD	53.88 (37.08–61.04)	49 (42.87–60.80)	34.54 (21.10–50.90)	0.2207^a

CKD: Chronic Kidney Disease, PLHIV: People Living with HIV, hs-CRP: high sensitivity C Reactive Protein, eGFR: estimated Glomerular Filtration Rate. Non-parametric variables expressed as medians and interquartile. Kruskall-Wallis’s test was used. ^me: median, ^IQR: interquartile, ^a: Kruskall-Walli’s test, *: Statistical Significance

ISSN: 1471-2369